Please ensure Javascript is enabled for purposes of website accessibility

Why Aptose Biosciences Stock Sank Today

By Keith Speights – Apr 27, 2020 at 2:29PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Investors weren't excited by the biotech's preliminary results from an early-stage clinical study.

What happened

Shares of Aptose Biosciences (APTO 2.86%) were sinking 11.9% as of 3:13 p.m. EDT on Monday. The decline came after the company presented preliminary clinical data from an early-stage clinical study evaluating CG-806 in treating relapsed or refractory chronic lymphocytic leukemia (CLL), small lymphocytic leukemia (SLL), or non-Hodgkin lymphoma (NHL). The presentation was included in the American Association for Cancer Research (AACR) Virtual Annual Meeting. 

So what

Aptose's results included only limited information. The company said that the study has completed three dose levels with no drug-related severe adverse events reported so far.

Gloved hand holding a test tube

Image source: Getty Images.

In particular, Aptose mentioned two patients, one treated with a 150-milligram dose of CG-806 twice daily and another treated with a 300-milligram dose twice daily. Neither patient has experienced a dose-limiting toxicity. The dose given to the first patient has been escalated to the 450-milligram level twice per day.

Investors seem to have been disappointed, though, that Aptose didn't reveal much in the way of how effective CG-806 has been in the early-stage study. The company did, however, state that its experimental drug "demonstrates favorable steady state pharmacokinetics," and that phospho-BTK antibody levels were lowered after exposure to plasma from the first patient and were completely abrogated with plasma from the second patient, which hints at the possibility of efficacy.

Now what

Aptose plans to present new data from higher dose cohorts at a future medical conference. The early-stage study evaluating CG-806 is expected to wrap up in late 2020.

The next key catalyst for the biotech stock could take place as early as next week. Aptose is scheduled to provide its first-quarter update on May 5.

Keith Speights has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Aptose Biosciences Inc. Stock Quote
Aptose Biosciences Inc.
APTO
$0.56 (2.86%) $0.02

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
327%
 
S&P 500 Returns
105%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 09/28/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.